Genetic engineering of a recombinant fusion possessing anti-tumor F(ab')2 and tumor necrosis factor

Journal of Biotechnology

Volumn 53, Issue 1, 1997, Pages 3-12

  Xiang, Jim ^a   Moyana, Terence ^a   Qi, Yumin ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

chimeric anti TAG72 antibody; fusion protein; tumor necrosis factor

Indexed keywords

AFFINITY CHROMATOGRAPHY; ANTIBODIES; ANTIGEN-ANTIBODY REACTIONS; ANTIGENS; BIOASSAY; BIOSYNTHESIS; CELLS; DNA SEQUENCES; GENES; IMMUNOLOGY; MOLECULAR STRUCTURE; PURIFICATION;

ALPHA TUMOR NECROSIS FACTOR (TNF); FUSION PROTEIN; WESTERN BLOTTING;

GENETIC ENGINEERING;

TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY;

ARTICLE; BIOTECHNOLOGY; CYTOMETRY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENETIC ENGINEERING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; TUMOR CELL;

ADENOCARCINOMA; AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, NEOPLASM; COLONIC NEOPLASMS; GENETIC VECTORS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOHISTOCHEMISTRY; MICE; MOLECULAR SEQUENCE DATA; PROTEIN ENGINEERING; RECOMBINANT FUSION PROTEINS; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0343035605     PISSN: 01681656     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-1656(96)01639-2     Document Type: Article

References (18)

1. Asher, A., Mule, J., Reichert, C., Shiloni, E. and Rosenberg, S. (1987) Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J. Immunol. 138, 963-974.
2. Boyd, M. and Xiang, J. (1994) Molecular cloning and expression of functional cDNA genes of a mouse/human chimeric antibody rcM4. Tumori. 80, 473-480.
3. Creaven, P., Plager, J., Dupere, S., Huben, R., Takita, H., Mittelman, A. and Proefrock, A. (1987) Phase-I clinical trial of recombinant human necrosis factor. Cancer Chemother. Pharmac. 20, 137-144.
4. Fitzgerald, D., Willingham, M., Cardarelli, C., Hamada, H., Tsuruo, T., Gottesman, M. and Pastan, I. (1987) A monoclonal antibody-pseudomanas toxin conjugate that specifically kills multidrug-resistant cells. Proc. Natl. Acad. Sci. U.S.A. 84, 4288-4292.
5. Hand, P., Calvo, B., Milenic, D., Yokota, T., Finch, M., Snoy, P., Garmestani, K., Gansow, O., Schlom, J. and Kashmiri, S. (1992) Comparative biological properties of a recombinant chimeric anti-carcinoma mAb and a recombinant aglycosylated variant. Cancer Immunol. Immunother. 35, 165-174.
6. Harlow, E. and Lane, D. (1988) Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
7. Harven, E., Fradet, Y., Connolly, J., Hana, W., He, S., Wang, Y., Choi, B., McGroarty, R., Bootsma, G., Tilup, A. and Christensen, H. (1992) Antibody drug carrier for immunotherapy of superficial bladder cancer. Ultrastructural studies. Cancer Res. 52, 3131-3137.
8. Kjeldsen, T., Clausen, H., Hirohashi, S., Ogawa, T., Iijima, H. and Hakomori, S. (1988) Preparation and characterization of monoclonal antibodies to the tumor-associated O-linked sialosy 2.6α-N-acetyl-galactosaminyl (Sialosyl-Tn) epitope. Cancer Res. 48, 2214-2220.
9. Moritz, T., Niederle, N., Baumann, J., May, D., Kurschel, E., Osieka, R., Kempeni, J., Schick, E. and Schmidt, C. (1989) Phase I study of recombinant human tumor necrosis factor α in advanced malignant disease. Cancer Immunol. Immunother. 29, 144-149.
10. Sabzevari, H., Gillies, S., Muller, B., Pancookk, J. and Reisfeld, R. (1994) A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. Proc. Natl. Acad. Sci. U.S.A. 91, 9626-9632.
11. Schneider, W., Wensel, T., Stryer, L. and Oi, V. (1988) Genetically engineered immunoglobulins reveal structural features controlling segment flexibility. Proc. Natl. Acad. Sci. U.S.A. 85, 2509-2513.
12. Sherman, M., Spriggs, D., Arthur, K., Immamura, K., Frei, E. and Kufe, D. (1988) Recombinant human tumor necrosis factor administered as a 5-day continuous infusion in cancer patients: phase toxicity and effects on lipid metabolism. J. Clin. Oncol. 6, 344-359.
13. Spriggs, D., Sherman, M., Michie, H., Arthur, K., Imamura, K., Wilmore, D., Frei, E. and Kufe, D. (1988) Recombinant human tumor necrosis factor administerred as a 24-h intravenous infusion, a phase I and pharmacologic study. J. Nat. Cancer. Inst. 80, 1039-1044.
14. Thor, A., Ohuchi, N., Szpak, C., Johnston, W. and Schlom, J. (1986) Distribution of the oncofetal antigen, tumor-associated glycoprotein-72 defined by the monoclonal antibody B72.3. Cancer Res. 46, 3118-3124.
15. Xiang, J., Roder, J. and Hozumi, N. (1990) Production of murine V/human Cr1 chimeric anti-TAG72 antibody using V region cDNA amplified by PCR. Mol. Immunol. 27, 809-817.
16. Xiang, J., Moyana, T., Kalra, J., Hamilton, T. and Qi, Y. (1992) Construction and characterization of a high affinity chimeric anti-colorectal carcinoma antibody ccM4. Mol. Biother. 4, 174-183.
17. Xiang, J., Moyana, T. and Qi, Y. (1996) Targeting of gamma interferon to tumor cells by a recombinant fusion protein secreted by myeloma cells. Hum. Antibodies Hybridomas. 7, 1-10.
18. Yang, J., Moyana, T. and Xiang, J. (1995) A genetically engineered single-chain FV/TNF molecule possesses the anti-tumor immunoreactivity of FV as well as the cytotoxic activity of tumor necrosis factor. Mol. Immunol. 32, 873-881.